LPA and peripheral arterial disease: Therefore, genetic evidence suggests that new treatments currently under development that lower serum Lp(a) levels have the potential to lower the risk of PAD.29,30 A phase 3 randomized, double blinded, placebo-controlled trial is currently evaluating the effect on Lp(a) lowering by antisense approach (AKCEA-APO(a)-LRx), on cardiovascular outcomes.30–32